151 related articles for article (PubMed ID: 31664946)
1. Clinical significance of serum PSA in breast cancer patients.
Hanamura T; Ohno K; Hokibara S; Murasawa H; Nakamura T; Watanabe H; Kaizuka M; Sawano S; Koyama H; Ito KI
BMC Cancer; 2019 Oct; 19(1):1021. PubMed ID: 31664946
[TBL] [Abstract][Full Text] [Related]
2. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
3. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
[TBL] [Abstract][Full Text] [Related]
4. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
5. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
6. Search for genetic factor association with cancer-free prostate-specific antigen level elevation on the basis of a genome-wide association study in the Korean population.
Choe EK; Lee Y; Cho JY; Choi SH; Park B; Lee JE; Cho EY
Eur J Cancer Prev; 2018 Sep; 27(5):453-460. PubMed ID: 28471803
[TBL] [Abstract][Full Text] [Related]
7. Serum level of prostate-specific antigen (PSA) in women with breast cancer.
Mashkoor FC; Al-Asadi JN; Al-Naama LM
Cancer Epidemiol; 2013 Oct; 37(5):613-8. PubMed ID: 23932967
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.
Secreto G; Venturelli E; Meneghini E; Carcangiu ML; Paolini B; Agresti R; Pellitteri C; Berrino F; Gion M; Cogliati P; Saragò G; Micheli A
BMC Cancer; 2012 Dec; 12():599. PubMed ID: 23241075
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
[TBL] [Abstract][Full Text] [Related]
10. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy.
Kono M; Fujii T; Lyons GR; Huo L; Bassett R; Gong Y; Karuturi MS; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2016 Nov; 160(1):101-109. PubMed ID: 27663436
[TBL] [Abstract][Full Text] [Related]
11. [Impact of AR-V7 expression on overall survival for patients with metastatic prostate cancer].
Qu Y; Ye D; Dai B; Kong Y; Chang K; Gu C; Sun Z; Zhang H; Zhu Y; Shi G
Zhonghua Wai Ke Za Zhi; 2014 Aug; 52(8):622-6. PubMed ID: 25370765
[TBL] [Abstract][Full Text] [Related]
12. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk.
Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP
Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers associated with breast cancer are associated with obesity.
Sauter ER; Scott S; Hewett J; Kliethermes B; Ruhlen RL; Basarakodu K; de la Torre R
Cancer Detect Prev; 2008; 32(2):149-55. PubMed ID: 18639389
[TBL] [Abstract][Full Text] [Related]
14. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
16. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
17. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
Hashimoto K; Tabata H; Shindo T; Tanaka T; Hashimoto J; Inoue R; Muranaka T; Hotta H; Yanase M; Kunishima Y; Takahashi A; Masumori N;
Urol Oncol; 2019 Jul; 37(7):485-491. PubMed ID: 31103335
[TBL] [Abstract][Full Text] [Related]
18. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA
Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263
[TBL] [Abstract][Full Text] [Related]
19. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.
Wellberg EA; Checkley LA; Giles ED; Johnson SJ; Oljira R; Wahdan-Alaswad R; Foright RM; Dooley G; Edgerton SM; Jindal S; Johnson GC; Richer JK; Kabos P; Thor AD; Schedin P; MacLean PS; Anderson SM
Horm Cancer; 2017 Dec; 8(5-6):269-285. PubMed ID: 28741260
[TBL] [Abstract][Full Text] [Related]
20. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]